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Introduction {#sec006}
============

Glucosamine and chondroitin (G&C), often taken together as a single pill and used for osteoarthritis, are among the most popular dietary supplements in the US \[[@pone.0117534.ref001]\]. G&C are considered safe, with no known major adverse side effects \[[@pone.0117534.ref002]\]. While the efficacy of these supplements for treatment of osteoarthritis remains debated \[[@pone.0117534.ref002],[@pone.0117534.ref003]\], recent studies suggest that they may have potential for reducing risk of other chronic diseases, such as cancer. In the VITamins And Lifestyle (VITAL) study, a large (n = 77,738) prospective cohort, we reported that use of G&C supplements is associated with a 27--35% lower incidence of colorectal cancer \[[@pone.0117534.ref004]\], a 26--28% lower incidence of lung cancer \[[@pone.0117534.ref004]\], 17% lower overall mortality \[[@pone.0117534.ref005]\], and a 13% lower cancer mortality \[[@pone.0117534.ref006]\]. These findings on G&C were the most consistent results across endpoints among the 30 supplements that were the focus of the VITAL study.

It is generally well-accepted that chronic inflammation contributes to carcinogenesis \[[@pone.0117534.ref007]\]. The majority of cellular events involved in the inflammation process require nuclear factor kappa B (NK-κB), a transcription factor that plays a central role in the generation of cytokines, chemokines and other soluble factors involved in the immune response. Similarly, excess reactive species characteristic of oxidative stress can damage cell membranes and DNA \[[@pone.0117534.ref008]\], and are thought to contribute to genomic instability and development of cancer \[[@pone.0117534.ref009]\]. Several lines of compelling evidence from *in vitro* and preclinical studies support a possible role for G&C in reducing inflammation \[[@pone.0117534.ref010]--[@pone.0117534.ref013]\]. A limited number of human observational and randomized studies also suggest that G&C lower systemic biomarkers of inflammation and oxidative stress \[[@pone.0117534.ref014],[@pone.0117534.ref015]\]; however, no human intervention trials have evaluated the potential for G&C to reduce inflammation or alter other pathways relevant to carcinogenesis in healthy individuals free of chronic inflammatory conditions.

Our objectives in the present study were two-fold. Our first aim was to determine the effect of a common dose of G&C on a panel of serum inflammation biomarkers \[high sensitivity C-reactive protein (CRP), interleukin-6 (IL-6), and soluble tumor necrosis factor receptors I & II (sTNFRI and II); a urinary biomarker of inflammation, prostaglandin E~2~-metabolite (PGE-M); and a urinary biomarker of oxidative stress, F~2~-isoprostane (F~2~-IsoP)\]. Secondly, we sought to characterize intervention-induced changes in plasma proteomic patterns via pathway analyses in response to G&C compared to placebo. Results from this study may help determine the anti-inflammatory potential of G&C in humans, and may identify other possible pathways that may be modulated with use of G&C.

Methods {#sec007}
=======

Research Design {#sec008}
---------------

The study was a randomized, double-blind, placebo-controlled, crossover trial comparing supplemental glucosamine and chondroitin to placebo. The protocol for this trial and supporting CONSORT checklist are available as supporting information; see [S1 Protocol](#pone.0117534.s004){ref-type="supplementary-material"} and [S1 CONSORT Checklist](#pone.0117534.s001){ref-type="supplementary-material"}. As this was a small pilot trial with the aim of enrolling a sample of 20 individuals, participants were randomly assigned by the project manager to begin with either the active or placebo intervention period in blocks of two using a pre-determined randomization template alternating placebo and G&C interventions. Each new recruit was assigned to the next available assignment. Each intervention period lasted 28 days with a 28 day washout period between the two interventions. All study activities were carried out at the Fred Hutchinson Cancer Research Center (FHCRC), Seattle, Washington. Recruitment, enrollment, trial, and sample collection took place from October 2012 to July 2013. The study protocol was approved by the FHCRC Institutional Review Board on July 11, 2012, with continuation approval obtained through May 18, 2015. All participants gave informed written consent. The authors confirm that all ongoing and related trials for this intervention are registered. This trial was registered at <http://www.clinicaltrials.gov> as NCT01682694.

Participants {#sec009}
------------

Participants were healthy, overweight \[BMI (body mass index) \>25 and ≤32.5 kg/m^2^\], non-smoking, aged 20--55 years, and recruited from the greater Seattle area. We recruited men and women who were overweight because inflammation biomarkers are unlikely to decrease measurably in response to an intervention among individuals who have very low systemic inflammation at baseline, and BMI is a strong predictor of both CRP and IL-6 \[[@pone.0117534.ref016],[@pone.0117534.ref017]\]. Methods for recruitment included flyers posted on university campuses in Seattle and at FHCRC, an informational website, and advertisements in campus and local neighborhood newspapers.

Screening occurred in two phases. In the first phase, individuals were screened for eligibility using a self-administered questionnaire and were excluded for any of the following: chronic medical illness; history of gastrointestinal, hepatic, or renal disorders; inflammatory conditions (including autoimmune and inflammatory diseases); pregnancy or lactation; currently on a weight loss diet; BMI \<25 or ≥32.5 kg/m^2^; alcohol intake \>2 drinks/day (2 drinks defined as 720 ml beer, 240 ml wine or 90 ml spirits); current use of prescription or over-the-counter medications other than oral contraceptives and hormone-secreting IUDs, multivitamins or use of aspirin or NSAIDs more than 2 days per week; inability to swallow pills; known allergy to shellfish; not willing to take pills made from shellfish or animal sources; or intention to relocate out of the study area within the next 4 months. Eligible individuals were invited to a study information session and those interested in participating provided informed written consent.

In the second phase of screening, prospective participants attended a screening clinic visit at the FHCRC Prevention Center. Height and weight were measured to ensure BMI requirements were met. Because body fat can vary among similar BMIs, body fat percentage was assessed by whole-body dual-energy X-ray absorptiometry (DEXA) scanning using a GE Lunar DPX-Pro densitometer (GE Healthcare, Milwaukee, WI). Blood was drawn in the morning after an overnight fast and was used for analysis of renal (blood urea nitrogen: 7--25 mg/dl; creatinine: 0.50--1.10 mg/dl for females; 0.60--1.35 mg/dl for males; eGFR ≥ 60 ml/min/1.73m^2^; sodium: 135--146 μmol/l; potassium: 3.5--5.3 μmol/l; chloride: 98--110 μmol/l), liver (albumin: 3.6--5.1 g/dl; globulin: 2.1--3.7; total bilirubin: 0.2--1.2 mg/dl; alkaline phosphatase: 40--115 U/L; AST: 10--30 U/L for females; 10--40 U/L for males; ALT: 6--40 U/L for females; 9--60 U/L for males), and metabolic function (glucose: 65--99 mg/dl). Individuals with normal laboratory values were invited to participate in the study.

A total of 27 individuals underwent screening activities. Seven were ineligible prior to randomization, six due to high fasting glucose concentrations and one due to abnormal liver enzyme concentrations. Twenty individuals (n = 10 men; n = 10 women) were randomized. One female was asked to drop out after completing only one intervention period because she started a new diet and exercise program that might have had effects on biomarker measures. Because inflammation biomarkers are influenced by minor infections (e.g., colds) and other illnesses \[[@pone.0117534.ref018]\], participants were instructed to delay clinic visits until they were no longer ill; however, one male participant attended a clinic visit at the onset of a cold and was also excluded, leaving a sample size of 18 (9 men and 9 women; [Fig. 1](#pone.0117534.g001){ref-type="fig"}).

![CONSORT Flow diagram of participants in the glucosamine and chondroitin (G&C) randomized, placebo-controlled trial.](pone.0117534.g001){#pone.0117534.g001}

Glucosamine and Chondroitin Supplements {#sec010}
---------------------------------------

Our aim was to evaluate G&C as used in population settings. Thus, dosing was based on the common starting dose recommended by the product manufacturer, which is similar across G&C products. The active treatment was 1500 mg/d FCHG49 glucosamine hydrochloride (GHCl) + 1200 mg/d TRH122 sodium chondroitin sulfate (CS) taken as 3 capsules daily with each capsule containing 500 mg GHCl and 400 CS. Crystalline cellulose was used as an inactive filler, and both active treatment and placebo were encapsulated in clear gelatin capsules. The placebo was similar in appearance and contained only the inactive filler. Both G&C and the placebo were generated from a single lot of source materials and donated by Nutramax Laboratories Consumer Care, Inc. (Edgewood, MD). Supplement bottles were provided by the manufacturer with a single printed label containing the letters "A" or "B". To maintain double-blinding for both participants and investigators, the randomization algorithm was sent in a sealed envelope to an investigator uninvolved in the day to day study activities; unblinding of the interventions was done at the time of data analysis. Participants were contacted by study staff at the mid-point and end of each intervention period to assess any possible adverse experiences and compliance. No adverse events were reported. Extra pills were included in each supplement bottle in the event that a Day 28 study visit was delayed, and so that adherence percentages (pills supplied---pills returned/days elapsed) could be calculated as an additional compliance measure. Composition of analysis testing was performed by an independent laboratory (Tampa Bay Analytical Research, Inc., Clearwater, FL) in collaboration with the NIH Office of Dietary Supplements. HPLC-UV analysis of a subset of capsules confirmed that mean G&C content was within specifications. No G&C was detected in the placebo capsules and no microbial products were detected in either capsule type.

Specimen Collection {#sec011}
-------------------

Biological samples were collected at baseline (screening visit) and after each 28-day intervention period in the morning after a minimum of a 12-hour overnight fast. For blood samples, tubes without additive were allowed to clot at room temperature for 30 minutes before they were centrifuged to separate the serum. Blood was also drawn into a tube containing EDTA for plasma. Both serum and plasma were aliquoted and stored at -80°C.

Participants were given a urine collection kit and instructions before each visit, and brought the specimen with them to the clinic visit. Participants were instructed to collect all of their urine for the 12 hours prior to their morning clinic visit at baseline and on Day 28 of each intervention period. Urine-void times were recorded and any uncollected voids noted. Urine specimens were stored at 4°C until delivery to the FHCRC the morning following collection. Urine volume was measured and aliquots stored at 80°C.

Laboratory Analyses {#sec012}
-------------------

### Serum Inflammation Biomarkers {#sec013}

All assays were performed on never-thawed samples with the exception of CRP which is stable through freeze-thaw cycles, and was measured in samples that had been thawed once \[[@pone.0117534.ref019]\]. No observations were below the limit of detection for any markers. Assays for all inflammation markers have been described \[[@pone.0117534.ref020]\]. Intra and inter-assay CVs for CRP, IL-6, and sTNFRI and II were 1.7% and 5.5%; 3.7% and 5.8%; 2.1% and 1.7%; and 2.3% and 5.6%, respectively.

### Urinary Inflammation and Oxidative Stress Biomarkers {#sec014}

Urinary PGE-M (11-alpha-hydroxy-9,15-dioxo-2,3,4,5-tetranor-prostane-1,20-dioic acid), the stable metabolite of PGE~2~, was assayed at the Vanderbilt Eicosanoid Core Laboratory (VECL, Nashville, TN) by a liquid chromatography/mass spectrometry (LC/MS) method, as previously described \[[@pone.0117534.ref021]\]. Urinary F~2~-IsoP was measured by gas-chromatography (GC)-negative-ion chemical ionization MS by the VECL using an Agilent 5973 GC/MS system (Santa Clara, CA) \[[@pone.0117534.ref022]\].

### Proteomics Analysis of Plasma {#sec015}

Plasma samples were evaluated on a customized antibody array populated with \~3,000 full-length antibodies, printed in triplicate on a single microarray \[[@pone.0117534.ref023]--[@pone.0117534.ref025]\]. Briefly, to analyze proteins in the plasma samples, we depleted albumin and IgG. Protein (200 μg) from the two participant blood draws were each labeled with Cy5. Each sample was combined with reference sample and pipetted at the microarray/coverslip junction followed by incubation for 90 min at room temperature in the dark. Unbound proteins were removed by washing and the slides scanned for Cy3 and Cy5 fluorescence in an Axon Genepix 4000B scanner. The Cy5/Cy3 ratio determined the relative concentration of protein compared to reference. The array contains antibodies to cytokines (e.g., interleukins 1A, 1B, 2, 3, 4, 4R, 5, 6, 7, 8, 10, 12A, 13, 15, 16, 17D, 18, 19, 20, 24, 28A, and 34 and interleukin receptors 2RA, 2RA, 3RA, 4R, 5RA, 6ST, 17RA and 17RB), adipokines, proteins involved in apoptosis, angiogenesis, T-cell activation/infiltration, inflammation/prostaglandins, insulin, insulin resistance toll-like receptor (TLR), transforming growth factor (TGF)-β, and STAT signaling pathways that have been reported to be deregulated in a variety of diseases. Most (\>85%) antibodies on the array had coefficients of variation, for triplicates, of less than 10% \[[@pone.0117534.ref023],[@pone.0117534.ref024],[@pone.0117534.ref026],[@pone.0117534.ref027]\]. Detailed protocol descriptions of array fabrication, plasma treatment, plasma labeling, incubation, and scanning have been published elsewhere \[[@pone.0117534.ref023],[@pone.0117534.ref027]\].

Array Analysis and Normalization {#sec016}
--------------------------------

Array data contain a format identical to two-channel gene expression arrays and analysis proceeds analogously. The array image was scanned using a GenePix 4000B (Axon Instruments) scanner. The numerical data processed by Genepix Pro 6.0 were imported to Limma 2.4.11 (Linear Models for Micro Array, a Bioconductor R package \[[@pone.0117534.ref028]\]). For each antibody, fold-change of the signal (red channel) was compared to the reference (green channel). The M value was calculated as Red/Green, where Red and Green were computed after background correction using the "normexp" method \[[@pone.0117534.ref029]\]. Saturated array spots were flagged and triplicate antibodies with coefficients of variation \>10% were removed. Experimental variation was normalized using within-array print-tip loess and between-array quartile normalization. Triplicate features were summarized using their median. M values were standardized such that the mean value and standard deviation of the placebo group was set to zero and one, respectively. After all processing, data were available for analysis on a total of 2938 antibodies.

Statistical Analysis {#sec017}
--------------------

All inflammatory and oxidative stress biomarkers were log-transformed to improve the normality of the distributions prior to analysis. Results are presented as geometric means with 95% confidence intervals (CI). Generalized estimating equations (GEE), which account for correlation of repeated measures, were used to assess the effects of G&C versus placebo on inflammation and oxidative stress. Analysis of each Day 28 inflammatory or oxidative stress biomarker was adjusted for the same biomarker concentration at Day 0 for each treatment period. Sex, age, and body-fat percent were selected *a priori* as additional covariates for adjustment in the model. We also evaluated the effect of treatment period but because it did not affect the point estimates, (i.e., carryover effects were not contributing to outcome measures), we did not include treatment period in the models. The two-sided *P* value for statistical significance for biomarkers of inflammation and oxidative stress was set at \<0.05. Analyses were performed using Stata statistical software (v13.1, StataCorp, College Station, TX).

Proteomics data were analyzed by performing paired *t*-tests to determine statistically significant differences between the two interventions, after adjusting for covariate effects, including hybridization day, and plate and box position by linear regression. Antibody markers were ranked on the basis of p value and effect sizes, so that a positive value indicates that the antibody expression was greater after supplementation with G&C compared to placebo, and a negative value indicates lower expression. To further integrate the antibody at the protein level, multiple duplicated antibodies for the same protein that did not have at least two significant results with the effect size going in the same direction were excluded. Among those proteins with at least two concordant significant results, the most significant antibody was reported for the top 100 proteins. Gene Set Enrichment Analyses, the evaluation of microarray data at the level of "gene groups" that share a common biologic theme or cellular location, were carried out based on the *t*-test results using Kyoto Encyclopedia of Genes and Genomes (KEGG) \[[@pone.0117534.ref030]\] and the gene set database Gene Ontology (GO) \[[@pone.0117534.ref031]\] downloaded from the Molecular Signatures Database (MSigDB, <http://www.broadinstitute.org/gsea/msigdb/index.jsp>). We used a Bonferroni correction to determine significant differences within the KEGG pathway \[*P* \<3.85x10^-4^; (0.05/130, the total number of pathways evaluated in KEGG)\], the GO pathway \[*P*\<5.18x10^-5^; (e.g., 0.05/966, the total number of pathways evaluated in GO)\], and for the individual proteins \[*P* \<1.70x10^-5^; (0.05/2,938, the total number of antibodies on the array)\].

Results {#sec018}
=======

[Table 1](#pone.0117534.t001){ref-type="table"} summarizes the demographic and baseline characteristics of the 18 study participants stratified by sex. Baseline measures of all inflammatory biomarkers were higher among men, while F~2~-isoP was lower.

10.1371/journal.pone.0117534.t001

###### Characteristics of participants randomized in the crossover trial of glucosamine and chondroitin at baseline (n = 18).

![](pone.0117534.t001){#pone.0117534.t001g}

                                                                           Men (n = 9)   Women (n = 9)
  ------------------------------------------------------------------------ ------------- ---------------
  [Personal characteristics]{.ul} [^1^](#t001fn001){ref-type="table-fn"}                 
   Age (y)                                                                 40 (8.0)      38 (8.8)
   BMI (kg/m[^2^](#t001fn002){ref-type="table-fn"})                        27 (2.8)      29 (2.4)
   Body fat (%)[^2^](#t001fn002){ref-type="table-fn"}                      32 (4.6)      39 (4.1)
  [Inflammation biomarkers]{.ul} [^3^](#t001fn003){ref-type="table-fn"}                  
   CRP mg/l                                                                1.18 (1.3)    0.77 (1.1)
   IL-6 pg/ml                                                              1.19 (0.9)    0.52 (0.2)
   sTNFRI pg/ml                                                            1119 (287)    654 (398)
   sTNFRII pg/ml                                                           5832 (1280)   5398 (620)
   PGE-M (ng/mg creatinine)                                                8.32 (4.7)    3.83 (1.3)
   F~2~-isoprostane (ng/mg creatinine)                                     1.00 (0.4)    1.13 (0.4)

^1^Mean (SD)

^2^Measured by Dual X-ray Absorptiometry (DEXA)

^3^Geometric mean (geometric SD)

Statistically significantly lower geometric mean CRP concentrations were observed after the G&C intervention compared to placebo (-23%, *P* = 0.048; [Table 2](#pone.0117534.t002){ref-type="table"}). No significant differences were observed in the other inflammation or oxidative stress biomarkers assessed, although they were slightly lower after G&C supplementation with the exception of the soluble TNF receptors, which increased by 1--3%.

10.1371/journal.pone.0117534.t002

###### Inflammatory and oxidative stress biomarker concentrations after placebo and glucosamine and chondroitin intervention.

![](pone.0117534.t002){#pone.0117534.t002g}

  Biomarker                             Placebo (N = 18)   Glucosamine & Chondroitin (N = 18)   *P*
  ------------------------------------- ------------------ ------------------------------------ -------
  CRP (mg/l)                            1.17 (0.17)        0.90 (0.13)                          0.048
  IL-6 (pg/ml)                          0.89 (0.10)        0.81 (0.09)                          0.27
  sTNFRI (pg/ml)                        871.3 (15.6)       901.6 (15.7)                         0.17
  sTNFRII (pg/ml)                       5558 (103)         5633 (104)                           0.34
  PGE-M (ng/mg creatinine)              6.15 (0.41)        5.89 (0.39)                          0.60
  F~2~-isoprostane (ng/mg creatinine)   1.20 (0.08)        1.10 (0.08)                          0.38

^1^Least squares geometric means (geometric SD) from GEE model adjusted for baseline values, age, sex, and body fat percent

Of the \~3,000 antibodies on the proteomics array, 2,938 were detected. We conducted gene-set enrichment pathway analyses using both KEGG and GO database tools ([Table 3](#pone.0117534.t003){ref-type="table"}). Five pathways in the KEGG pathway analysis remained statistically significant after a Bonferroni correction (nominal p-values 7 x 10^-10^ to 4 x 10^-5^)---cytokine-cytokine receptor interaction, JAK/STAT signaling pathway, intestinal immune network for IGA production, leukocyte transendothelial migration, and ubiquitin-mediated proteolysis. Twenty-five pathways in the GO pathway analyses remained statistically significant after Bonferroni correction (p values 3 x 10^-16^ to 1 x 10^-5^), including cytokine activity, receptor binding, hematopoietin/interferon (classD 200 domain) cytokine receptor binding, growth factor activity, extracellular region, chemokine activity, extracellular space, G-protein coupled receptor binding, chemokine receptor binding, extracellular region part, locomotory behavior, membrane fraction, response to external stimulus, regulation of actin filament length, regulation of actin polymerization and/or depolymerization, regulation of cellular component size, behavior, actin polymerization and/or depolymerization, regulation of organelle organization and biogenesis, regulation of cytoskeleton organization and biogenesis, response to biotic stimulus, nucleus, microtubule-based process, response to other organism and cell fraction. In each analysis, cytokine activity/cytokine receptor binding was the most significantly affected pathway. With the exception of ubiquitin-mediated proteolysis, and proteins located in the nucleus, all pathways were down-regulated after G&C supplementation.

10.1371/journal.pone.0117534.t003

###### Significantly different pathways comparing glucosamine and chondroitin supplementation to placebo via gene-set enrichment analysis in Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) databases (n = 18).

![](pone.0117534.t003){#pone.0117534.t003g}

  Pathway/ Genes (count)[^1^](#t003fn001){ref-type="table-fn"}   Probes in Array[^2^](#t003fn002){ref-type="table-fn"}   Positive Probes[^3^](#t003fn003){ref-type="table-fn"}   Negative Probes[^4^](#t003fn004){ref-type="table-fn"}   *P* value[\*](#t003fn006){ref-type="table-fn"}   Genes in the Pathway
  -------------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ***KEGG*[^*5*^](#t003fn005){ref-type="table-fn"}**                                                                                                                                                                                                                                      
   Cytokine-Cytokine Receptor Interaction                                                                                                                                                                                                                                                 
   101                                                           368                                                     70                                                      165                                                     7.2x10^-12^                                      CSF3;IL13;IL8;EGFR;TNF;LIFR;CXCL12;PRLR;CCL20;IL4;IL6;IL10;CCL5;TNFRSF9;PRL;FLT4;IL5RA; CD40LG;IL28A;KIT;VEGFA;IL24;TNFRSF17;LEP;CD27;IFNGR1;IL15;IFNB1;CCL14;TNFRSF1B;IL20; IL15RA;FLT3;FASLG;IL18;CSF2;MPL;IL1A;IL1RAP;IL18RAP;PDGFRA;CSF1;LEPR;TNFRSF11B; TNFRSF10B;IL2RA;NGFR;IL10RB;FIGF;CXCL11;CSF3R;IFNG;TGFB1;CXCR4;PF4;CCR5;IL6ST; TGFBR2;IL3RA;CCL4;TGFB3;IFNAR1;IL12A;TNFSF8;PDGFRB;IL4R;MET;EGF;IL7;TGFB2;KDR;CXCL5;TNFSF13B;CCL27;IL5;FLT1;IL13RA1;CCR7;TNFSF9;CXCR3;BMPR1A;IL19;TNFRSF10A;TNFRSF8; FAS;INHBE;PDGFA;BMP7;INHBC;CCL21;CCR2;GHR;CCR6;PDGFB;VEGFB;OSM;CD70;CXCL10; IFNA1;IL12RB2;INHBA
   JAK/STAT Signaling                                                                                                                                                                                                                                                                     
  71                                                             211                                                     39                                                      104                                                     4.4x10^-8^                                       CSF3;IL13;LIFR;PRLR;IL4;IL6;IL10;CCND3;PRL;IL5RA;IL28A;IL24;LEP;IFNGR1;IL15;IFNB1;PIK3CB; STAT5A;CCND1;SOCS7;MYC;IL20;IL15RA;CSF2;MPL;PIM1;CBLB;LEPR;STAT1;IL2RA;IL10RB;CSF3R;IFNG;CSH1;GRB2;PIK3CA;IL6ST;IL3RA;IFNAR1;IL12A;AKT1;IL4R;IL7;PTPN6;STAT5B;PTPN11;IL5; STAT4;IL13RA1;BCL2L1;SOCS2;SOS1;STAT3;IL19;CCND2;SPRED1;AKT2;CBL;JAK3;TYK2;GHR; SOCS1;SPRY1;PIK3R1;CREBBP;OSM;PIK3CD;IRF9;CBLC;IFNA1;IL12RB2
   Intestinal Immune Network for IGA Production                                                                                                                                                                                                                                           
  15                                                             88                                                      17                                                      51                                                      8.7x10^-6^                                       CXCL12;IL4;IL6;IL10;CD40LG;CD86;TNFRSF17;IL15;IL15RA;TGFB1;CXCR4;CD28;TNFSF13B;CCL27; IL5
   Leukocyte Transendothelial Migration                                                                                                                                                                                                                                                   
  38                                                             109                                                     19                                                      53                                                      3.5x10^-5^                                       CXCL12;CLDN18;ITGB1;PTK2B;RAC1;MMP9;PLCG1;PIK3CB;THY1;VCL;BCAR1;VASP;MMP2; VCAM1;ACTB;PECAM1;RAP1A;RHOA;PTK2;CXCR4;PIK3CA;ITGAL;ITK;GNAI3;PTPN11;VAV3;PXN; CDH5;CLDN6;RASSF5;PRKCA;PIK3R1;MAPK11;PIK3CD;CLDN1;ITGAM;SIPA1;MAPK14
   Ubiquitin-Mediated Proteolysis                                                                                                                                                                                                                                                         
  23                                                             37                                                      19                                                      3                                                       4.1x10^-5^                                       BRCA1;MDM2;BIRC2;BIRC3;MAP3K1;CBLB;CUL4A;CUL2;CUL5;XIAP;CUL4B;CUL7;UBE2S;FANCL; CUL1;CBL;UBR5;SOCS1;ANAPC2;SKP2;VHL;FBXW7;CBLC
  ***GO*** [^***5***^](#t003fn005){ref-type="table-fn"}                                                                                                                                                                                                                                   
   Cytokine Activity                                                                                                                                                                                                                                                                      
   41                                                            177                                                     23                                                      109                                                     2.6x10^-16^                                      CSF3;IL8;TNF;CXCL12;CCL20;IL4;CCL5;PRL;CD40LG;VEGFA;BMP4;ERBB2;IL20;CSF2;CSF1; TNFRSF11B;FIGF;CXCL11;IFNG;C5;IL1RN;PF4;CCL4;IL12A;IL7;TGFB2;TRIP6;CXCL5;CCL27;IL5;IL19; INHA;SPRED1;GDF15;CCL21;PIK3R1;OSM;CXCL10;MUC4;MIF;INHBA
   Receptor Binding                                                                                                                                                                                                                                                                       
   109                                                           280                                                     48                                                      151                                                     2.5x10^-14^                                      CSF3;HBEGF;IL8;EFNB3;BID;IRS1;TNF;CXCL12;CCL20;EREG;IL4;CCL5;LCK;NCK1;DLL4;ANXA1; NCOR2;PRL;NMB;CD40LG;TGFA;FBLN5;SLC9A3R1;VEGFA;ICAM2;GRN;NCOA6;EFNB1;THY1; BMP4;STOML2;ERBB2;IL20;CSF2;ANG;CSF1;PCSK9;ALCAM;FGF1;TNFRSF11B;CYTL1;VWF;GAST; FIGF;F2R;ADAM23;ADAM9;CXCL11;IFNG;COL4A3;TGFB1;GFRA1;IGF1;C5;GRB2;NPY;MED12; PTHLH;MBL2;EDN1;IL1RN;GABARAP;AREG;ADAMTS13;STC2;DLL1;PF4;CCL4;EFNA5;TGFB3; IL12A;EGF;IL7;TGFB2;TRIP6;CXCL5;CCL27;FGF3;IL5;WNT5A;SOCS2;FADD;TGFB1I1;F2;IL19; NUP62;INHA;TNXB;JMJD1C;GABARAPL2;SPRED1;GDF15;INHBC;RLN1;CCL21;CCR2;CHGB;SOCS1;DST;PIK3R1;OSM;CXCL10;MUC4;TDGF1;CASP8AP2;MIF;JAG2;SHC1;INHBA
   Hematopoietin/Interferon Cytokine Receptor Activity                                                                                                                                                                                                                                    
   8                                                             68                                                      5                                                       48                                                      1.7x10^-12^                                      CSF3;IL4;PRL;CSF2;IFNG;IL7;IL5;OSM
   Growth Factor Activity                                                                                                                                                                                                                                                                 
   18                                                            79                                                      8                                                       51                                                      1.0x10^-10^                                      CSF3;IL4;TGFA;GRN;CSF2;CSF1;FGF1;IL1RN;AREG;EGF;IL7;TRIP6;FGF3;IL5;INHA;TDGF1;JAG2; INHBA
   Extracellular Region                                                                                                                                                                                                                                                                   
   140                                                           293                                                     58                                                      145                                                     1.3x10^-8^                                       THBS4;CSF3;HBEGF;COMP;IL8;DSPP;CCL20;MMP3;EREG;IL4;IL6;TFF3;PLA2G5;CTGF;IL5RA;CPN1;CD5L;DGCR6;ORM1;FBLN5;PNLIPRP2;MMP9;VEGFA;DCD;S100A7;COL18A1;LEP;TFRC;IL15; CCL14;MMP2;PSAP;ERBB2;IL20;SERPINA5;IL18;LGALS3BP;ANG;IL1A;GSN;MMP7;PCSK9;SOD1; CDA;PRG2;CDH13;TNFRSF11B;CYTL1;CP;SFRP4;VWF;COL8A1;LGALS7;TPT1;SERPINA1;FIGF; CFHR1;SPINT2;FBN1;COL4A3;TGFB1;PI3;IL16;LOXL1;KLK5;C5;FGG;WNT2B;NPY;PTHLH;MBL2; EDN1;IL1RN;AREG;ADAMTS13;SFRP1;SFN;PRSS8;MMP13;CCL4;EFNA5;IL12A;TINAG;IL7;TGFB2; SHH;LAMC1;IGFBP1;FGF3;FRZB;MMP10;IL5;WNT5A;DKK3;KLK10;APCS;F7;MMP11;FLT1;APOD; LAMB1;ANGPTL4;CRLF1;CPB2;FBLN2;POSTN;PDZD2;LYZ;KLK6;MUC5AC;NUCB1;F2;C2;MSMB; INHA;FSTL1;TNXB;F13A1;PTX3;GDF15;KLK8;VTN;INHBC;KLK13;COL5A1;COL5A3;PLG;DST;OSM; FGF2;RBP4;ADM;A1BG;FGFBP1;LALBA;REG3A;FBN2;MIF;DMBT1;INHBA
   Chemokine Activity                                                                                                                                                                                                                                                                     
   12                                                            70                                                      9                                                       49                                                      1.7x10^-8^                                       IL8;CXCL12;CCL20;CCL5;CXCL11;C5;PF4;CCL4;CXCL5;CCL27;CCL21;CXCL10
   Extracellular Space                                                                                                                                                                                                                                                                    
   83                                                            196                                                     37                                                      105                                                     2.2x10^-8^                                       CSF3;HBEGF;IL8;CCL20;MMP3;EREG;IL4;IL6;IL5RA;CPN1;CD5L;ORM1;MMP9;VEGFA;LEP;IL15; CCL14;MMP2;PSAP;LGALS3BP;ANG;IL1A;MMP7;PCSK9;SOD1;CDH13;CYTL1;CP;SFRP4;LGALS7; TPT1;SERPINA1;FIGF;CFHR1;FBN1;TGFB1;IL16;KLK5;C5;FGG;WNT2B;NPY;PTHLH;MBL2;EDN1; IL1RN;AREG;SFRP1;SFN;PRSS8;MMP13;CCL4;EFNA5;IL12A;SHH;IGFBP1;MMP10;IL5;WNT5A; DKK3;APCS;FLT1;APOD;CRLF1;CPB2;LYZ;NUCB1;F2;C2;MSMB;INHA;FSTL1;KLK8;VTN;PLG;OSM; FGF2;RBP4;ADM;FGFBP1;LALBA;REG3A;INHBA
   G-Protein-Coupled Receptor Binding                                                                                                                                                                                                                                                     
   14                                                            75                                                      10                                                      51                                                      2.3x10^-8^                                       IL8;CXCL12;CCL20;CCL5;SLC9A3R1;CXCL11;C5;PF4;CCL4;CXCL5;CCL27;CCL21;CCR2;CXCL10
   Chemokine Receptor Binding                                                                                                                                                                                                                                                             
   13                                                            72                                                      9                                                       49                                                      2.4x10^-7^                                       IL8;CXCL12;CCL20;CCL5;CXCL11;C5;PF4;CCL4;CXCL5;CCL27;CCL21;CCR2;CXCL10
   Extracellular Region                                                                                                                                                                                                                                                                   
   106                                                           227                                                     46                                                      118                                                     7.3x10^-8^                                       THBS4;CSF3;HBEGF;COMP;IL8;DSPP;CCL20;MMP3;EREG;IL4;IL6;CTGF;IL5RA;CPN1;CD5L;DGCR6;ORM1;FBLN5;MMP9;VEGFA;COL18A1;LEP;IL15;CCL14;MMP2;PSAP;LGALS3BP;ANG;IL1A;MMP7;PCSK9;SOD1;CDH13;CYTL1;CP;SFRP4;COL8A1;LGALS7;TPT1;SERPINA1;FIGF;CFHR1;FBN1; COL4A3;TGFB1;PI3;IL16;KLK5;C5;FGG;WNT2B;NPY;PTHLH;MBL2;EDN1;IL1RN;AREG;ADAMTS13;SFRP1;SFN;PRSS8;MMP13;CCL4;EFNA5;IL12A;TINAG;SHH;LAMC1;IGFBP1;MMP10;IL5;WNT5A; DKK3;APCS;MMP11;FLT1;APOD;LAMB1;CRLF1;CPB2;FBLN2;POSTN;LYZ;MUC5AC;NUCB1;F2;C2;MSMB;INHA;FSTL1;TNXB;KLK8;VTN;COL5A1;COL5A3;PLG;DST;OSM;FGF2;RBP4;ADM;FGFBP1; LALBA;REG3A;FBN2;INHBA
   Locomotory Behavior                                                                                                                                                                                                                                                                    
   33                                                            112                                                     17                                                      64                                                      2.4x10^-7^                                       IL8;CXCL12;CCL20;IL4;IL10;CCL5;PIK3CB;SOD1;MAPK1;FOSL1;CDH13;PLD1;CXCL11;C5;CXCR4; DEFA1;PF4;CCR5;TGFB2;CXCL5;CCL27;MAP2K1;CCR7;CXCR3;PLAUR;RALBP1;CCL21;CCR2;CCR6; FGF2;HRAS;CXCL10;MAPK14
   Membrane Fraction                                                                                                                                                                                                                                                                      
   42                                                            113                                                     17                                                      59                                                      2.5x10^-7^                                       CEACAM1;VCP;BID;IRS1;EEA1;GALK1;LYVE1;IL15;BCAR1;FOLR3;FUT3;LY6D;ATP8B1;STX16;JUP; FUT4;STEAP2;CD59;HLAB;GP1BA;PRKCE;DPP10;APOB;XRCC6;SPTAN1;ABCB1;DAG1;CLIC1;CDH5;PTGS1;ABCA3;SLC1A1;LRP12;AMFR;PRKCA;SELP;PRKCZ;CD70;LRP1;PDLIM5;FOLH1;SLC2A1
   Response to External Stimulus                                                                                                                                                                                                                                                          
   108                                                           249                                                     47                                                      122                                                     2.9x10^-7^                                       IL13;IL8;ITGB3;CXCL12;WAS;CCL20;EREG;IL4;IL10;CCL5;FOS;CD97;F13B;MMRN1;PLAT;ANXA1; CTGF;CD40LG;ORM1;RPS6KA5;RAC1;S100A8;LEP;LYVE1;SSTR2;F5;PIK3CB;MDK;SELE;IL20;TFPI; IL1A;IL1RAP;IL18RAP;PCSK9;SOD1;MAPK1;FOSL1;CDH13;S100A9;CD59;VWF;IL10RB;PLD1; CFHR1;F2R;GP1BA;GCGR;CXCL11;TGFB1;TP53;C5;CHST2;NMI;CXCR4;NPY;MBL2;DEFA1;STC2; PF4;CCR5;MGLL;CCL4;CRP;CDKN1A;CHMP1A;TNFAIP6;TGFB2;CXCL5;CCL27;NF1;IL5;APCS;F7; MAP2K1;CCR7;RTN4RL2;LYZ;CXCR3;PPARG;CDKN2B;F2;S100A12;AOAH;C2;SERPINE1;INHA; F13A1;PLAUR;PTX3;KLK8;RALBP1;PRDX5;CCL21;PLG;CCR2;CCR6;FGF2;HRAS;RIPK2;TACR1;ADM;CXCL10;PROC;MAPK14;ITGA2;RELA;INHBA
   Regulation of Actin Filament Length                                                                                                                                                                                                                                                    
   4                                                             53                                                      6                                                       35                                                      8.1x10^-7^                                       CXCL12;NCK1;GSN;CAPG
   Regulation of Actin Polymerization and/or Depolymerization                                                                                                                                                                                                                             
   4                                                             53                                                      6                                                       35                                                      8.1x10^-7^                                       CXCL12;NCK1;GSN;CAPG
   Regulation of Cellular Component Size                                                                                                                                                                                                                                                  
   4                                                             53                                                      6                                                       35                                                      8.1x10^-7^                                       CXCL12;NCK1;GSN;CAPG
   Behavior                                                                                                                                                                                                                                                                               
  41                                                             126                                                     22                                                      69                                                      1.4x10^-6^                                       IL8;CXCL12;CCL20;IL4;IL10;CCL5;IL1RAPL1;CRHBP;LEP;PIK3CB;HPRT1;SOD1;MAPK1;FOSL1; CDH13;PLD1;CXCL11;C5;CXCR4;NPY;DEFA1;PF4;CCR5;TGFB2;CXCL5;CCL27;NF1;MAP2K1;CCR7; CXCR3;PLAUR;KLK8;RALBP1;CCL21;CCR2;CCR6;FGF2;HRAS;TACR1;CXCL10;MAPK14
   Actin Polymerization and/or Depolymerization                                                                                                                                                                                                                                           
  9                                                              62                                                      8                                                       38                                                      3.1x10^-6^                                       CXCL12;NCK1;RAC1;DSTN;ANG;GSN;WIPF1;CAPG;WASL
   Regulation of Organelle Organization and Biogenesis                                                                                                                                                                                                                                    
  11                                                             65                                                      9                                                       39                                                      5.2x10^-6^                                       CXCL12;KATNB1;NCK1;MAPRE1;GSN;ARAP1;APC;CAPG;NEXN;NF2;TSC1
   Regulation of Cytoskeleton Organization and Biogenesis                                                                                                                                                                                                                                 
  11                                                             65                                                      9                                                       39                                                      5.2x10^-6^                                       CXCL12;KATNB1;NCK1;MAPRE1;GSN;ARAP1;APC;CAPG;NEXN;NF2;TSC1
   Response to Biotic Stimulus                                                                                                                                                                                                                                                            
  26                                                             99                                                      16                                                      52                                                      5.2x10^-6^                                       VCP;TNF;CXCL12;GSK3B;FGR;IL10;CCL5;S100A7;BCL3;HSPB1;CD24;IFNGR1;FOSL1;BCL2;PTPRC; TP53;CXCR4;TLR3;CCL4;IFNAR1;IL12A;VAPB;S100A12;AMFR;LALBA;DMBT1
   Nucleus                                                                                                                                                                                                                                                                                
  198                                                            318                                                     113                                                     80                                                      1.3x10^-5^                                       SUZ12;GADD45A;BCAS2;VCP;EGFR;HLF;AXIN2;IRS1;GSK3B;FOS;EGR1;KPNA2;BRCA1;CNOT7; SMAD4;CEP290;XPA;MDM2;PARK7;NBN;NCOR2;BRCA2;STK17A;LGALS3;DEK;FOXO3;RPS6KA5; HEXIM1;GZMB;MECP2;CDK1;S100A7;ERG;SUFU;PARP1;SIK1;BCL3;NCOA6;PTGS2;RAD54L; MCM2;PPIA;SPDYA;BIRC3;KDM5B;PTMS;DLGAP5;BCL6;PHB;TP63;CDK6;CRK;MYC;STIP1;NDC80;S100A11;ANG;PTGES3;SOD1;ABL1;BTG1;ACTB;USP4;PPARA;PPIE;FOSL1;FANCA;CYCS;BCL2; METTL3;CHEK1;STAT1;SIN3A;RALY;USF1;CCNA2;MGMT;ASH2L;WRN;GLI3;MALT1;ERCC5;EPC1; CDK9;ESR2;LYN;NFKB2;FOXO1;CDKN1B;TP53;HNRNPU;HTATIP2;APC;PIN1;MED12;PBX3;TBP; G3BP1;GNL3;CDK2;ATXN3;RXRB;FLNA;NOTCH4;MEF2A;CDKN2A;SRF;IGFBP3;USP7;NME1; GATA2;CCNB1;CREB1;MYCN;CHMP1A;CSNK2A1;EZH2;MAPKAPK3;PPM1D;JUN;RARB;NFKBIA; RGS12;XRCC6;PHB2;NPM1;MAML2;HIF1A;NF1;TLE1;TAF1;SMARCA2;SUMO1;SENP2;NAP1L1; NOTCH1;NAP1L3;AXIN1;CFL1;XRCC4;PDZD2;STAT3;CDKN2B;KDM5A;MSH6;CSTF1;CIDEA;CEBPG;PPIG;CDK4;NUP62;CLIC1;MSMB;EED;MRPL40;MLH3;PTGS1;MUTYH;KHDRBS3;LIMK2;NLRP5; RXRA;PA2G4;NOTCH2;DUSP4;ATF4;HDAC1;UBR5;RB1;CDKN2C;RAD50;RAD51;REC8;NF2;SENP1;RANBP1;HDAC2;PSEN2;CDK2AP1;VHL;NCBP2;UTP20;CCS;LSM1;ZBTB22;IRF9;BUB1B;EHD2;EIF6;RAD52;TOB2;ETS2;XRCC5;MAPK14;CASP8AP2;RELA;TRAF4;PTMA
   Microtubule-Based Process                                                                                                                                                                                                                                                              
  13                                                             67                                                      11                                                      40                                                      2.3x10^-5^                                       CXCL12;KATNB1;NCK1;KPNA2;MAPRE1;GSN;ARAP1;TTK;APC;MAP7;CAPG;NF2;TSC1
   Response to Other Organism                                                                                                                                                                                                                                                             
  20                                                             87                                                      14                                                      46                                                      3.5x10^-5^                                       TNF;CXCL12;FGR;IL10;CCL5;S100A7;BCL3;CD24;IFNGR1;FOSL1;BCL2;PTPRC;CXCR4;TLR3;CCL4; IFNAR1;IL12A;S100A12;LALBA;DMBT1
   Cell Fraction                                                                                                                                                                                                                                                                          
  76                                                             181                                                     38                                                      82                                                      3.8x10^-5^                                       CEACAM1;IL13;VCP;BID;IRS1;TNF;CD55;MDM2;NMB;CD40LG;FBLN5;CRHBP;EEA1;GALK1;LYVE1;AGT;FSHB;EFNB1;IL15;BCAR1;FOLR3;FUT3;LY6D;ATP8B1;STX16;DUSP6;JUP;FUT4;STEAP2;CD59;CYTL1;NTS;HLAB;SPINT2;GP1BA;ANXA2;TP53;PRKCE;WISP2;EDN1;DPP10;APOB;XRCC6; TNFSF13B;WNT5A;SPTAN1;CTTN;ABCB1;DAG1;F2;ACP1;S100A12;CLIC1;FAS;CDH5;PTGS1; ABCA3;SLC1A1;GCLM;LRP12;AMFR;PRKCA;UBR5;CCR2;SOD3;SELP;PRKCZ;CCS;ADM;CD70; WISP1;LRP1;REG3A;PDLIM5;FOLH1;SLC2A1

^1^ Among the total number of genes in the pathway, number of unique genes in our array data

^2^ Total number of corresponding antibody probes in the assay

^3^ Among the significant probes, via paired t-test comparing G&C to placebo, the number that have an effect size \>0

^4^ Among the significant probes, via paired t-test comparing G&C to placebo, the number that have an effect size \<0

^5^ GO = Gene Ontology; KEGG = Kyoto Encyclopedia of Genes and Genomes

\*All pathways listed were statistically significant with Bonferroni correction (*P* \<3.85x10^-4^ for KEGG pathway; *P*\<5.18x10^-5^ for GO pathway)

Of the individual proteins, 508 were statistically significantly different between the two interventions with a Bonferroni correction (p \< 1.7 x 10^-5^). The 100 most significant antibodies (p values 3 x 10^-16^ to 1 x 10^-9^) are given in [Table 4](#pone.0117534.t004){ref-type="table"}.

10.1371/journal.pone.0117534.t004

###### Top 100 (of 508) individual protein antibodies significantly different after glucosamine and chondroitin supplementation versus placebo intervention periods (n = 18).

![](pone.0117534.t004){#pone.0117534.t004g}

  Gene[^1^](#t004fn001){ref-type="table-fn"}   Function[^2^](#t004fn002){ref-type="table-fn"}                                                                                                                            Effect size[^3^](#t004fn003){ref-type="table-fn"}   *P* value[\*](#t004fn004){ref-type="table-fn"}
  -------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------- ------------------------------------------------
  CEACAM1                                      Cell-cell adhesion                                                                                                                                                        -2.45                                               8.7x10^-15^
  SUZ12                                        Proliferation and histone methyltransferase activity \[[@pone.0117534.ref050],[@pone.0117534.ref051]\]                                                                    1.09                                                1.7x10^-14^
  THBS4                                        Cell-to-cell and cell-to-matrix interactions, extracellular mitogen                                                                                                       -1.88                                               2.1x10^-14^
  GADD45A                                      Induced in response to DNA damage                                                                                                                                         -1.37                                               2.8x10^-14^
  ITGA5                                        Adhesion and cell-surface mediated signaling                                                                                                                              -1.54                                               9.7x10^-14^
  ITGB4                                        Adhesion and cell-surface mediated signaling                                                                                                                              -1.89                                               1.2 x10^-13^
  CSF3(GCSF)^§^                                Cytokine involved in hematopoiesis and induction of granulocytes                                                                                                          -3.06                                               2.1 x10^-13^
  PKNOX1                                       RNA polymerase II distal enhancer                                                                                                                                         1.43                                                2.8 x10^-13^
  IL13^§^                                      Immunoregulatory cytokine involved in inhibition of allergic reaction, particularly in the airways                                                                        -6.29                                               3.5 x10^-13^
  C1orf38                                      Mediates macrophage inflammatory response                                                                                                                                 3.67                                                4.6 x10^-13^
  SON                                          Splicing co-factor for cell-cycle progression and DNA-repair, involved in differentiation of hematopoietic cells                                                          1.02                                                6.4 x10^-13^
  MUC3B                                        Provides protective barrier against infectious agents at mucosal surfaces                                                                                                 3.83                                                1.3 x10^-12^
  RUNX1                                        Subunit of transcription factor that binds to many enhancers and promoters, involved in development of normal hematopoiesis                                               3.93                                                1.4 x10^-12^
  IL17D                                        Cytokine involved in the stimulation of other cytokines, e.g., IL6, IL8, and CSF                                                                                          -2.27                                               1.6 x10^-12^
  BCAS2                                        Component of pre-mRNA splicesome complex                                                                                                                                  1.72                                                2.3 x10^-12^
  KCNE3                                        Modulates gating kinetics of potassium voltage channel complexes                                                                                                          1.75                                                3.2 x10^-12^
  CD44                                         Cell adhesion and migration, receptor for hyaluronic acid                                                                                                                 1.50                                                3.3 x10^-12^
  VEPH1                                        Function unknown                                                                                                                                                          1.80                                                3.7 x10^-12^
  HBEGF                                        Normal heart function, smooth muscle cell proliferation, may be involved in macrophage mediated proliferation                                                             -1.47                                               5.2 x10^-12^
  VCP                                          Putative ATP-binding protein in vesicle transport and fusion, 26S proteasome function and assembly of peroxisomes                                                         -2.10                                               6.8 x10^-12^
  COMP                                         Structural integrity of cartilage, potent suppressor of apoptosis in chondrocytes                                                                                         -2.08                                               7.4 x10^-12^
  IL8^§^                                       Chemokine, chemoattractant and potent angiogenic factor                                                                                                                   -2.35                                               9.9 x10^-12^
  CAPN3 (NCL1)                                 Intracellular protease, binds to titin                                                                                                                                    -2.09                                               1.0 x10^-11^
  GCM2                                         Transcription factor regulating parathyroid development                                                                                                                   1.23                                                1.0 x10^-11^
  PKC                                          Regulation of cell growth and immune responses                                                                                                                            -0.89                                               1.3 x10^-11^
  LASP1                                        Regulation of actin-based cytoskeletal activities                                                                                                                         -1.42                                               1.4 x10^-11^
  SPP1 (Osteopontin)                           Attachment of osteoclasts to the mineralized bone matrix; also a cytokine that upregulates expression of interferon-gamma and interleukin-12                              -6.45                                               1.7 x10^-11^
  EFNB3                                        Ligand for Eph receptors involved in migration, repulsion and adhesion during neuronal, vascular and epithelial development                                               -3.24                                               1.9 x10^-11^
  HOXA4                                        Transcription factor that may regulate gene expression, morphogenesis and differentiation                                                                                 1.88                                                2.3 x10^-11^
  IL1β                                         Cytokine involved in inflammatory response                                                                                                                                -2.65                                               2.3 x10^-11^
  EGFR^§^                                      Cell proliferation                                                                                                                                                        1.80                                                3.1 x10^-11^
  PRKCQ                                        Kinase involved in diverse cellular signaling pathways including T-cell activation, proliferation, differentiation and survival                                           -1.68                                               3.1 x10^-11^
  ENO1                                         Multifunctional glycolytic enzyme involved in glycolysis, growth control, hypoxia tolerance and allergic response                                                         -3.37                                               3.2 x10^-11^
  SULF1                                        Inhibits signaling by heparin-dependent growth factors, diminishes proliferation and facilitates apoptosis                                                                2.39                                                3.2 x10^-11^
  MUC6                                         Modulates the composition of the protective mucus layer related to acid secretion or presence of bacteria in the lumen                                                    1.43                                                3.4 x10^-11^
  HDA-1                                        Histone deacetylase; regulation of gene expression                                                                                                                        1.35                                                4.3 x10^-11^
  TACSTD2                                      Cell surface receptor that transduces calcium signals                                                                                                                     1.20                                                4.9 x10^-11^
  AXIN2                                        Inhibitor of Wnt signaling pathway, down-regulates beta-catenin                                                                                                           1.89                                                5.1 x10^-11^
  IRS1                                         Mediates the control of various cellular processes by insulin                                                                                                             -1.37                                               5.1 x10^-11^
  VPS25                                        Formation and sorting of endosomal proteins destined for lysosomal degradation                                                                                            -1.26                                               5.6 x10^-11^
  ANKRD11                                      Inhibits ligand-dependent activation of transcription                                                                                                                     1.34                                                5.8 x10^-11^
  DEFA1;A1B                                    Antibacterial, fungicidal and antiviral activities                                                                                                                        -1.01                                               6.5 x10^-11^
  RASGRF2                                      Signal coordination of mitogen-activated protein kinase pathways                                                                                                          1.07                                                8.3 x10^-11^
  ESM1                                         Expressed in endothelial cells in lung and kidney, regulated by cytokines                                                                                                 3.77                                                8.5 x10^-11^
  DSPP                                         Dentinogenesis                                                                                                                                                            2.18                                                8.6 x10^-11^
  BAG1                                         Anti-apoptotic factor                                                                                                                                                     1.52                                                9.3 x10^-11^
  NOV                                          Cell-adhesion, migration, proliferation, differentiation and survival                                                                                                     -1.79                                               9.3 x10^-11^
  LIFR^§^                                      Cytokine                                                                                                                                                                  -4.54                                               1.2 x10^-10^
  EXT2                                         Heparin sulfate bioysynthesis                                                                                                                                             1.16                                                1.2 x10^-10^
  CXCL12(SDF1)^§^                              Ligand for G-protein coupled receptor involved in inflammation                                                                                                            -1.57                                               1.2 x10^-10^
  CD55/DAF                                     Regulation of the complement cascade                                                                                                                                      1.90                                                1.3 x10^-10^
  LEF1                                         Involved in Wnt signaling and enhances T-cell receptor binding                                                                                                            2.58                                                1.4 x10^-10^
  LIN28B                                       Suppressor of microRNA biogenesis                                                                                                                                         1.40                                                1.4 x10^-10^
  PRLR^§^                                      Cytokine receptor, interacts with prolactin                                                                                                                               2.39                                                1.6 x10^-10^
  MASP1                                        Complement activation                                                                                                                                                     -1.99                                               1.7 x10^-10^
  KRT10                                        Cytoskeleton composition                                                                                                                                                  -1.56                                               1.8 x10^-10^
  WAS                                          Signal transducer for actin cytoskeleton                                                                                                                                  3.76                                                1.8 x10^-10^
  FSCN1                                        Actin-bundling protein                                                                                                                                                    -1.48                                               2.0 x10^-10^
  NAGLU                                        Degrades heparin sulfate                                                                                                                                                  -1.85                                               2.1 x10^-10^
  CCL20^x^                                     Chemotactic factor                                                                                                                                                        4.00                                                2.5 x10^-10^
  MMP3                                         Extracellular matrix degradation                                                                                                                                          1.61                                                2.6 x10^-10^
  DLAT                                         Pyruvate dehydrogenase complex component which catalyzes the conversion of pyruvate to acetyl CoA                                                                         -1.88                                               3.0 x10^-10^
  SP1                                          Activator or repressor of transcription of a battery of genes related to cell growth, apoptosis, differentiation and immune response                                      -1.46                                               3.0 x10^-10^
  EREG                                         Epidermal growth factor family member                                                                                                                                     -4.04                                               3.0 x10^-10^
  NOLA2                                        Ribosome biogenesis and telomere maintenance                                                                                                                              3.92                                                3.1 x10^-10^
  CALR3                                        Expressed in testis, may be required for sperm fertility                                                                                                                  -1.22                                               3.2 x10^-10^
  IL4^§^                                       Cytokine produced by activated T cells                                                                                                                                    -1.04                                               3.3 x10^-10^
  ARHGEF17                                     Exchange factor for RhoA GTPases                                                                                                                                          1.86                                                3.3 x10^-10^
  STMN1 (S15)                                  Regulation of filament system destabilization                                                                                                                             3.34                                                3.3 x10^-10^
  SPARC (Osteonectin)                          Calcification of collagen in bone; also regulates cell shape and growth through interactions with extracellular matrix and cytokines                                      -1.05                                               3.3 x10^-10^
  FGR                                          Negative regulator of cell migration and adhesion                                                                                                                         1.60                                                3.5 x10^-10^
  IL6^§^                                       Cytokine with diverse functions in inflammation, maturation of B cells, osteoblast formation, neuronal differentiation, hematopoiesis and energy mobilization in muscle   1.33                                                3.8 x10^-10^
  CCL5^§^                                      Chemoattractant for monocytes, memory T helper cells and eosinophils                                                                                                      -2.78                                               4.4 x10^-10^
  CSRP1                                        Cellular differentiation                                                                                                                                                  -1.11                                               4.9 x10^-10^
  PEPD                                         Recycling of proline, may be rate limiting for production of collagen                                                                                                     -1.27                                               5.0 x10^-10^
  LCK                                          Key signaling molecule in selection and maturation of developing T-cells                                                                                                  1.22                                                5.2 x10^-10^
  WNT3A                                        Cell-cell signaling during embyogenesis                                                                                                                                   -2.95                                               5.2 x10^-10^
  DEPDC1                                       Transcriptional co-repressor                                                                                                                                              2.52                                                5.5 x10^-10^
  KRT18                                        Uptake of thrombin-antithrombin complexes by hepatic cells; filament reorganization                                                                                       -1.56                                               5.5 x10^-10^
  UBC                                          Protein degradation                                                                                                                                                       -2.00                                               5.6 x10^-10^
  SERPINB5                                     Tumor suppressor                                                                                                                                                          1.27                                                6.1 x10^-10^
  CCSP-2                                       Marker for colon cancer                                                                                                                                                   -1.69                                               6.1 x10^-10^
  EGR1                                         Activates transcription of genes required for mitogenesis and differentiation                                                                                             1.36                                                6.3 x10^-10^
  DCN                                          Matrix assembly                                                                                                                                                           1.85                                                6.4 x10^-10^
  TNFRSF9^§^                                   TNF receptor family                                                                                                                                                       -3.59                                               6.9 x10^-10^
  CD142(F3)                                    Initiates blood coagulation                                                                                                                                               -1.29                                               7.3 x10^-10^
  NPEPL1                                       Aminopeptidase activity                                                                                                                                                   2.01                                                7.4 x10^-10^
  KPNA2                                        Nuclear transport of proteins                                                                                                                                             2.01                                                7.7 x10^-10^
  BRCA1                                        Tumor suppressor                                                                                                                                                          2.08                                                7.7 x10^-10^
  IER3                                         Anti-apoptotic factor                                                                                                                                                     2.56                                                7.8 x10^-10^
  PHLDA2                                       Tumor Suppressor                                                                                                                                                          -2.73                                               8.2 x10^-10^
  AK1                                          Cellular energy homeostasis and adenine nucleotide metabolism                                                                                                             2.40                                                8.5 x10^-10^
  F13B                                         Coagulation factor                                                                                                                                                        -3.38                                               8.5 x10^-10^
  GJA1 (pS373)                                 Gap junction protein                                                                                                                                                      1.99                                                8.8 x10^-10^
  STX11                                        Protein transport                                                                                                                                                         1.22                                                9.3 x10^-10^
  TLN1/TLN2                                    Cytoskeletal protein                                                                                                                                                      -1.64                                               9.3 x10^-10^
  PPP2CA                                       Negative control of cell-growth and division                                                                                                                              -2.08                                               9.4 x10^-10^
  FUT8                                         Catalyzes addition of fucose in alpha 1--6 linkages                                                                                                                       2.36                                                1.0 x10^-09^
  ITGA1                                        Adhesion and cell-surface mediated signaling                                                                                                                              -1.94                                               1.0 x10^-09^
  CNOT7                                        Negative regulator of cell proliferation                                                                                                                                  -1.34                                               1.1 x10^-09^

^1^Indicates that protein was in the GO (Gene Ontology) or KEGG (Kyoto Encyclopedia of Genes and Genomes) Cytokines pathway

^2^Information pertaining to function is derived from PubMed Gene and/or UniProtKB unless otherwise noted

^3^Values \>1 indicate greater antibody expression after supplementation with G&C compared to placebo; values \<1 indicate lower expression

\*All proteins listed were statistically significant with Bonferroni correction (*P* \<1.70x10^-5^)

Discussion {#sec019}
==========

In this randomized, crossover trial, we found that G&C supplementation statistically significantly lowered mean serum CRP concentrations by 23% compared to placebo. In support of this finding, "Cytokine activity" was the most significant pathway altered between the two interventions in both the GO and KEGG gene-set enrichment analyses, and was lower after G&C. Correspondingly, a number of individual cytokines and other inflammation-related factors were significantly lower in the proteomics panel, including several interleukins and chemokines.

Our results are in agreement with a growing body of *in vitro* and animal research which suggests that G&C have anti-inflammatory properties. Laboratory studies indicate that G&C inhibit NF-κB, by preventing the degradation of its inhibitory subunit, Iκ-B \[[@pone.0117534.ref010]\]. Thus, NF-κB is unable to translocate to the nucleus, where this transcription factor activates the expression of a battery of genes involved in inflammatory response and cell proliferation \[[@pone.0117534.ref032]\]. These anti-inflammatory effects have been corroborated *in vivo* in animal studies. In rabbits with induced atherosclerosis and chronic arthritis, treatment with G inhibited NF-κB activation and down-regulated COX-2 expression in peripheral blood mononuclear cells, while also decreasing circulating levels of CRP and IL-6 \[[@pone.0117534.ref033]\]. Further research has shown that mice fed a G-containing diet for 56 days had lower serum IL-6 and TNFα than mice fed a control diet \[[@pone.0117534.ref034]\]. Two recent studies reported that G&C administration has anti-inflammatory effects in the colon \[[@pone.0117534.ref035]\]. Bak, et al \[[@pone.0117534.ref013]\], reported reduced TNFα, interleukin-1β, and NF-κB mRNA expression in colonic mucosa in mice induced with colitis after supplementation of G at 0.10% diet (wet weight) compared to control for four weeks. Finally, in rats with chemically-induced colitis, treatment with G ameliorated symptoms of colitis, while decreasing both systemic and colonic inflammation, as measured by serum concentrations of IL-8 and amyloid P component, and colonic expression of NF-kB, IL-1β, and TNFα, respectively \[[@pone.0117534.ref035]\]. These studies are notable given our findings of decreased colorectal cancer incidence with use of G&C in the VITAL study \[[@pone.0117534.ref004]\], and significantly decreased concentrations of CEACAM1 (carcinoembryonic antigen-related cell adhesion molecule 1) in the present study. CEACAM1 is an immunoglobulin involved in cell-to-cell adhesion, and its overexpression is implicated in colorectal cancer \[[@pone.0117534.ref036]\]. Further, this protein was the most significantly altered protein between the two interventions (effect size-2.45; *P* = 8.7x10^-15^).

Despite the compelling results from *in vitro* and preclinical models, few studies have evaluated the effects of G&C on inflammation in humans. In a nationally representative sample of nearly 10,000 adults included the National Health and Nutrition Examination Study (NHANES), regular use of G&C compared to nonuse was associated with a \~20% lower mean concentrations of hsCRP \[[@pone.0117534.ref014]\]. In addition, we recently observed G&C use to be associated with 28--36% lower CRP concentrations, \[[@pone.0117534.ref037]\] and 40--47% lower oxidative stress, as measured by urinary prostaglandin F~2~α (PGF2α) \[[@pone.0117534.ref038]\] among a sub-set of 220 individuals in the VITAL cohort \[[@pone.0117534.ref015]\]. Only two randomized trials of G &/or C on markers of inflammation have been conducted. In a small trial, 36 osteoarthritis patients were given 1500 mg G and 675 mg C for twelve weeks \[[@pone.0117534.ref039]\]. A significant reduction in serum PGE~2~ was observed among the G&C treated group, with post-treatment levels similar to that of 25 age-matched healthy controls. The same group conducted a second trial in which 51 rheumatoid arthritis patients were randomized to receive either 1500 mg G or placebo for twelve weeks \[[@pone.0117534.ref040]\]. While treatment with G reduced serum MMP-3 levels, CRP concentrations remained unchanged. However, exposure was limited to G alone (without C) and patients continued taking regular medications throughout the study. Furthermore, as individuals with rheumatoid arthritis have higher levels of inflammation than the general population, the results of this study may not be generalizable to a healthy population.

Additional inflammation-related pathways that were significantly different between interventions with Bonferroni correction included JAK/STAT signaling, a signaling pathway for a broad range of cytokines and growth factors \[[@pone.0117534.ref041]\]; intestinal immune network for IgA production, which serves as the first line of defense against microorganisms in the intestinal mucosa \[[@pone.0117534.ref042]\]; leukocyte transendothelial migration, the movement of leukocytes from blood into tissues for immune surveillance and inflammation \[[@pone.0117534.ref043]\]; and hematopoietin/interferon cytokine receptor binding, which includes class I cytokines, mainly the interleukins, and growth factors. G-protein coupled receptors are involved in diverse biologic functions, but include roles in growth and regulation of inflammation \[[@pone.0117534.ref044]\]. As with the cytokine pathway, the majority of the probes in these pathways were less abundant after G&C as compared to placebo. In fact, of the 30 significant pathways, the majority of probes were less abundant in all but two pathways---ubiquitin-mediated proteolysis and proteins contained in the nucleus. Alterations in these other inflammation-related pathways suggest that G&C may have wider-ranging effects on inflammation beyond inhibition of transcription factor NF-kB.

Significant differences in other pathways between the interventions indicate that G&C may play a role in other biologic functions that have not been previously associated with this supplement. For example, pathways related to microtubule function, regulation of actin polymerization, filament length, cytoskeleton organization, and locomotory activity were lower after G&C. Although there is overlap among some genes representing the pathways, these differences suggest that G&C may have effects on cell division and motility, targets of a growing number of chemotherapeutic drugs \[[@pone.0117534.ref045]--[@pone.0117534.ref047]\]. Lower protein concentrations in pathways related to external and biotic stimulus, and other organisms were likely related to reduction in inflammation-related signaling, particularly given the antibodies contained on our assay. Other pathways that differed between the interventions were based on cellular component or location. The meaning of these differences in unrelated proteins, in terms of health consequences, is unclear.

Among the most significant individual proteins that were differentially abundant between the interventions in the proteomics analysis, several in the top ten were related to cell-adhesion (CEACAM, THBS4, ITGA and B). Other proteins with large effect sizes were IL-13 (down; -6.29), an immunoregulatory cytokine involved in inhibition of allergic reaction, particularly in the airways; osteopontin (down; -6.45), which is involved in the attachment of osteoclasts to the mineralized bone matrix, and is also a cytokine that upregulates the expression of interferon-gamma and IL-12; and C1orf38 (up; 3.67), involved in mediating macrophage inflammatory response. Consistent with the lower CRP concentrations measured in serum, CRP was also down-regulated in plasma on the antibody array (down; -0.5, P = 0.001) but was not significant with correction for multiple testing. As has been observed in many other serum/plasma studies \[[@pone.0117534.ref048],[@pone.0117534.ref049]\], some of the proteins with significant changes are normally cytoplasmic or nuclear, so their role as putative serum/plasma biomarkers is unclear. They could indicate sufficient apoptosis and/or necrosis of cells to be detectable and imply that this is reduced with G&C treatment.

This is the first randomized trial to evaluate the effects of G&C on inflammation in healthy adults, and the first to assess potential pathways perturbed by G&C using a broad proteomic screen and gene set enrichment analyses. A major strength of this study is that participants were healthy and free of underlying inflammatory conditions, and the stringent inclusion and exclusion criteria minimized effects of other factors that may affect inflammatory status, (e.g., age, tobacco or medication use, chronic health conditions). Despite the small sample size, many of the intervention effects in the proteomics pathway analyses and for individual proteins were highly significant, exceeding by orders of magnitude, the Bonferroni corrections and the effects observed in multiple previous analyses we have performed in which we compared plasma samples in cancer cases and controls \[[@pone.0117534.ref023],[@pone.0117534.ref026],[@pone.0117534.ref027]\]. Detection of these highly significant effects appears to be due to our use of the randomized, crossover, placebo-controlled design where each participant acted as his or her own control. A strength of the platform is the significant coverage of the proteome including many cytokines (\~3,000 proteins). Thus, it is a powerful approach for identifying pathways that change in response to an intervention. Furthermore, it is a powerful discovery method for identifying individual biomarkers that may play an important role in the process being studied. Individual protein results warrant validation by other means such as ELISA or immunoblot since the array uses only a single antibody to bind the protein from plasma and the indicated antibody could bind a protein in plasma that is not the one claimed by the manufacturer (i.e., the specificity of each antibody has not be determined). Finally, given the sample size of the current study, the anti-inflammatory properties of G&C need to be replicated in larger randomized trials and should evaluate sex-specific effects.

In summary, we found that G&C significantly reduced circulating CRP concentrations compared to placebo, and gene set enrichment analyses indicated that cytokine activity and other inflammation-related pathways were significantly decreased. These results are supported by *in vitro* and animal studies demonstrating anti-inflammatory properties of G&C, as well as human observational data which show an association between G&C use and lower concentrations of circulating CRP. Thus, there is now growing evidence that G&C reduce systemic inflammation in humans. This evidence may also provide a possible biologic mechanism to support prior findings that use of G&C supplements is associated with reduced lung and colon cancer and overall mortality. Future studies in larger samples and other populations are needed to determine the potential utility of G&C as a possible anti-inflammatory agent.
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